Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
1.
Pak J Pharm Sci ; 34(1): 185-196, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34248019

RESUMO

The role of nanobiotechnology in the treatment of diseases is limitless. In this review we tried to focus main aspects of nanotechnology in drug carrier systems for treatment and diagnosis of various diseases such as cancer, pulmonary diseases, infectious diseases, vaccine development, diabetes mellitus and the role of nanotechnology on our economy and its positive social impacts on our community. We discussed here about the different "Biotechnano Strategies" to develop new avenues and ultimately improve the treatment of multiple diseases.


Assuntos
Biotecnologia/tendências , Portadores de Fármacos/administração & dosagem , Nanotecnologia/tendências , Desenvolvimento de Vacinas/tendências , Animais , Biotecnologia/economia , Doenças Transmissíveis/tratamento farmacológico , Doenças Transmissíveis/economia , Portadores de Fármacos/economia , Humanos , Nanotecnologia/economia , Neoplasias/tratamento farmacológico , Neoplasias/economia , Desenvolvimento de Vacinas/economia
2.
J Vasc Interv Radiol ; 32(1): 2-12.e1, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-33160827

RESUMO

PURPOSE: To compare the cost-effectiveness of using doxorubicin-loaded drug-eluting embolic (DEE) transarterial chemoembolization versus that of using conventional transarterial chemoembolization for patients with unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A decision-analysis model was constructed over the lifespan of a payer's perspective. The model simulated the clinical course, including periprocedural complications, additional transarterial chemoembolization or other treatments (ablation, radioembolization, or systemic treatment), palliative care, and death, of patients with unresectable HCC. All clinical parameters were derived from the literature. Base case calculations, probabilistic sensitivity analyses, and multiple two-way sensitivity analyses were performed. RESULTS: In the base case calculations for patients with a median age of 67 years (range for conventional transarterial chemoembolization: 28-88 years, range for DEE-transarterial chemoembolization: 16-93 years), conventional transarterial chemoembolization yielded a health benefit of 2.11 quality-adjusted life years (QALY) at a cost of $125,324, whereas DEE-transarterial chemoembolization yielded 1.71 QALY for $144,816. In 10,000 Monte Carlo simulations, conventional transarterial chemoembolization continued to be a more cost-effective strategy. conventional transarterial chemoembolization was cost-effective when the complication risks for both the procedures were simultaneously varied from 0% to 30%. DEE-transarterial chemoembolization became cost-effective if the conventional transarterial chemoembolization mortality exceeded that of DEE-transarterial chemoembolization by 17% in absolute values. The two-way sensitivity analyses demonstrated that conventional transarterial chemoembolization was cost-effective until the risk of disease progression was >0.4% of that for DEE-transarterial chemoembolization in absolute values. Our analysis showed that DEE-transarterial chemoembolization would be more cost-effective if it offered >2.5% higher overall survival benefit than conventional transarterial chemoembolization in absolute values. CONCLUSIONS: Compared with DEE-transarterial chemoembolization, conventional transarterial chemoembolization yielded a higher number of QALY at a lower cost, making it the more cost-effective of the 2 modalities.


Assuntos
Antibióticos Antineoplásicos/administração & dosagem , Antibióticos Antineoplásicos/economia , Carcinoma Hepatocelular/tratamento farmacológico , Quimioembolização Terapêutica/economia , Doxorrubicina/administração & dosagem , Doxorrubicina/economia , Portadores de Fármacos/economia , Custos de Medicamentos , Neoplasias Hepáticas/tratamento farmacológico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibióticos Antineoplásicos/efeitos adversos , Carcinoma Hepatocelular/mortalidade , Carcinoma Hepatocelular/patologia , Quimioembolização Terapêutica/efeitos adversos , Quimioembolização Terapêutica/mortalidade , Tomada de Decisão Clínica , Redução de Custos , Análise Custo-Benefício , Técnicas de Apoio para a Decisão , Árvores de Decisões , Progressão da Doença , Doxorrubicina/efeitos adversos , Feminino , Humanos , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/patologia , Masculino , Pessoa de Meia-Idade , Modelos Econômicos , Qualidade de Vida , Anos de Vida Ajustados por Qualidade de Vida , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
3.
Int J Pharm ; 573: 118817, 2020 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-31678520

RESUMO

Transferosomes, also known as transfersomes, are ultradeformable vesicles for transdermal applications consisting of a lipid bilayer with phospholipids and an edge activator and an ethanol/aqueous core. Depending on the lipophilicity of the active substance, it can be encapsulated within the core or amongst the lipid bilayer. Compared to liposomes, transferosomes are able to reach intact deeper regions of the skin after topical administration delivering higher concentrations of active substances making them a successful drug delivery carrier for transdermal applications. Most transferosomes contain phosphatidylcholine (C18) as it is the most abundant lipid component of the cell membrane, and hence, it is highly tolerated for the skin, decreasing the risk of undesirable effects, such as hypersensitive reactions. The most common edge activators are surfactants such as sodium deoxycholate, Tween® 80 and Span® 80. Their chain length is optimal for intercalation within the C18 phospholipid bilayer. A wide variety of drugs has been successfully encapsulated within transferosomes such as phytocompounds like sinomenine or apigenin for rheumatoid arthritis and leukaemia respectively, small hydrophobic drugs but also macromolecules like insulin. The main factors to develop optimal transferosomal formulations (with high drug loading and nanometric size) are the optimal ratio between the main components as well as the critical process parameters for their manufacture. Application of quality by design (QbD), specifically design of experiments (DoE), is crucial to understand the interplay among all these factors not only during the preparation at lab scale but also in the scale-up process. Clinical trials of a licensed topical ketoprofen transferosomal gel have shown promising results in the alleviation of symptons in orthreothritis with non-severe skin and subcutaneous tissue disorders. However, the product was withdrawn from the market which probably was related to the higher cost of the medicine linked to the expensive manufacturing process required in the production of transferosomes compared to other conventional gel formulations. This example brings out the need for a careful formulation design to exploit the best properties of this drug delivery system as well as the development of manufacturing processes easily scalable at industrial level.


Assuntos
Portadores de Fármacos/química , Desenvolvimento de Medicamentos/métodos , Bicamadas Lipídicas/química , Fosfolipídeos/química , Pele/metabolismo , Administração Cutânea , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/economia , Antirreumáticos/administração & dosagem , Antirreumáticos/economia , Membrana Celular/metabolismo , Permeabilidade da Membrana Celular , Ensaios Clínicos como Assunto , Portadores de Fármacos/economia , Composição de Medicamentos/economia , Composição de Medicamentos/métodos , Desenvolvimento de Medicamentos/economia , Etanol/química , Humanos , Interações Hidrofóbicas e Hidrofílicas , Osteoartrite/tratamento farmacológico , Pele/citologia , Absorção Cutânea , Dermatopatias/tratamento farmacológico , Tensoativos/química , Água/química
5.
Mol Pharm ; 14(10): 3480-3488, 2017 10 02.
Artigo em Inglês | MEDLINE | ID: mdl-28929769

RESUMO

Clofazimine, a lipophilic (log P = 7.66) riminophenazine antibiotic approved by the US Food and Drug Administration (FDA) with a good safety record, was recently identified as a lead hit for cryptosporidiosis through a high-throughput phenotypic screen. Cryptosporidiosis requires fast-acting treatment as it leads to severe symptoms which, if untreated, result in morbidity for infants and small children. Consequently, a fast-releasing oral formulation of clofazimine in a water-dispersible form for pediatric administration is highly desirable. In this work, clofazimine nanoparticles were prepared with three surface stabilizers, hypromellose acetate succinate (HPMCAS), lecithin, and zein, using the flash nanoprecipitation (FNP) process. Drug encapsulation efficiencies of over 92% were achieved. Lyophilization and spray-drying were applied and optimized to produce redispersible nanoparticle powders. The release kinetics of these clofazimine nanoparticle powders in biorelevant media were measured and compared with those of crystalline clofazimine and the currently marketed formulation Lamprene. Remarkably improved dissolution rates and clofazimine supersaturation levels up to 90 times equilibrium solubility were observed with all clofazimine nanoparticles tested. Differential scanning calorimetry indicated a reduction of crystallinity of clofazimine in nanoparticles. These results strongly suggest that the new clofazimine nanoparticles prepared with affordable materials in this low-cost nanoparticle formulation process can be used as viable cryptosporidiosis therapeutics.


Assuntos
Antiparasitários/farmacologia , Clofazimina/farmacologia , Criptosporidiose/tratamento farmacológico , Portadores de Fármacos/química , Composição de Medicamentos/métodos , Desenho de Fármacos , Antiparasitários/economia , Antiparasitários/uso terapêutico , Varredura Diferencial de Calorimetria , Química Farmacêutica , Clofazimina/economia , Clofazimina/uso terapêutico , Cristalização , Dessecação , Portadores de Fármacos/economia , Composição de Medicamentos/economia , Liberação Controlada de Fármacos , Excipientes/química , Liofilização , Nanopartículas/química , Nanopartículas/economia , Tamanho da Partícula , Solubilidade , Fatores de Tempo
6.
Drug Deliv Transl Res ; 6(4): 392-8, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-26912190

RESUMO

Drug nanocrystals have rapidly evolved into a mature drug delivery strategy in the last decade, with almost 16 products currently on the market. Several "top-down" technologies are available in the market for generation of nanocrystals. Despite several advantages, very few bottom-up technologies have been explored for commercial purpose. This short communication highlights a novel, bottom-up, spray drying based technology-NanoCrySP-to generate drug nanocrystals. Nanocrystals are generated in the presence of non-polymeric excipients that act as crystallization inducer for the drug. Excipients encourage crystallization of drug by plasticization, primary heterogeneous nucleation, and imparting physical barrier to crystal growth. Nanocrystals have shown significant improvement in dissolution and thereby oral bioavailability. NanoCrySP technology is protected through patents in India, the USA, and the European Union. NanoCrySP can be utilized for (i) pharmaceutical development of new chemical entities, (ii) differentiated products of existing molecules, and (iii) generic drug products. The aggregation of drug nanocrystals generated using NanoCrySP poses significant challenges in the nanocrystal-based product development. Addition of stabilizers either during spray drying or during dissolution has shown beneficial effects.


Assuntos
Comércio , Portadores de Fármacos/química , Portadores de Fármacos/economia , Nanopartículas/economia , Tecnologia Farmacêutica/economia , Tecnologia Farmacêutica/métodos , Cristalização , Sistemas de Liberação de Medicamentos/economia , Sistemas de Liberação de Medicamentos/métodos , Excipientes/química , Humanos , Nanopartículas/química
7.
PLoS One ; 10(7): e0130253, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26161510

RESUMO

Mesoporous silica materials (MSMs) were synthesized economically using silica (SiO2) as a precursor via a modified alkaline fusion method. The MSM prepared at 500°C (MSM-500) had the highest surface area, pore size, and volume, and the results of isotherms and the kinetics of ibuprofen (IBP) removal indicated that MSM-500 had the highest sorption capacity and fastest removal speed vs. SBA-15 and zeolite. Compared with commercial granular activated carbon (GAC), MSM-500 had a ~100 times higher sorption rate at neutral pH. IBP uptake by MSM-500 was thermodynamically favorable at room temperature, which was interpreted as indicating relatively weak bonding because the entropy (∆adsS, -0.07 J mol(-1) K(-1)) was much smaller. Five times recycling tests revealed that MSM-500 had 83-87% recovery efficiencies and slower uptake speeds due to slight deformation of the outer pore structure. In the IBP delivery test, MSM-500 drug loading was 41%, higher than the reported value of SBA-15 (31%). The in vitro release of IBP was faster, almost 100%, reaching equilibrium within a few hours, indicating its effective loading and unloading characteristics. A cost analysis study revealed that the MSM was ~10-70 times cheaper than any other mesoporous silica material for the removal or delivery of IBP.


Assuntos
Anti-Inflamatórios não Esteroides/administração & dosagem , Portadores de Fármacos/química , Ibuprofeno/administração & dosagem , Dióxido de Silício/química , Adsorção , Anti-Inflamatórios não Esteroides/isolamento & purificação , Portadores de Fármacos/economia , Ibuprofeno/isolamento & purificação , Porosidade , Dióxido de Silício/economia , Termodinâmica
8.
J Clin Pharm Ther ; 40(1): 83-90, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25413186

RESUMO

WHAT IS KNOWN AND OBJECTIVE: Drug eluting beads (DEBs) theoretically improve the efficacy and safety of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Nonetheless, their economic profile has not been assessed. Our retrospective before/after study aimed to compare efficacy, safety and economic profile of two strategies of TACE without (Period 1) or with the possibility of using DEBs (Period 2). METHODS: All HCC patients treated by TACE in our hospital between March 2006 and May 2013 were included. Economic analyses were performed from the French Public Health Insurance point of view according to the French Diagnosis-Related Group prospective payment system and from the analytic accountability. RESULTS AND DISCUSSION: One hundred and sixty-one patients were included. Median time to treatment failure and overall survival were 13.1 and 23.8 months in Period 1 vs. 14.1 and 30.2 months in Period 2 (P = 0.45 and P = 0.40). Mean hospital durations and tariffs were 14.9 ± 7.7 days and € 11 472 ± 5901 in Period 1 vs. 12.4 ± 8.4 days and € 7654 ± 4625 in Period 2 (P = 0.03 and P < 10(-4) ). WHAT IS NEW AND CONCLUSION: The possibility of using DEBs did not improve the prognosis in HCC patients treated by TACE. Nonetheless, it had a better medico-economic profile.


Assuntos
Antineoplásicos/administração & dosagem , Carcinoma Hepatocelular/terapia , Quimioembolização Terapêutica/economia , Quimioembolização Terapêutica/métodos , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/economia , Neoplasias Hepáticas/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/economia , Carcinoma Hepatocelular/economia , Carcinoma Hepatocelular/mortalidade , Análise Custo-Benefício/economia , Análise Custo-Benefício/métodos , Doxorrubicina/administração & dosagem , Custos de Medicamentos , Óleo Etiodado/administração & dosagem , Óleo Etiodado/economia , Feminino , Humanos , Idarubicina/administração & dosagem , Idarubicina/economia , Neoplasias Hepáticas/economia , Neoplasias Hepáticas/mortalidade , Masculino , Microesferas , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Taxa de Sobrevida , Resultado do Tratamento
9.
Curr Drug Targets ; 15(5): 478-85, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24712518

RESUMO

Natural resources are widely used as raw materials by industries. In most cases, abundant byproducts with low economic interest are also generated from agro-industrial supply chains. There are several examples for the rational use of agro-industrial byproducts in the nanobiotechnology field aiming for the development of novel products and high value added processes. Such raw materials include carapaces, pelages, blood, bagasses, and straws. Molecules from such materials (e.g. chitosan, cellulose, and albumin) are used as scaffolds of unprecedented novel nanostructure. Research efforts comprising a combination of sustainability, nanobiotechnology, and nanomedicine have emerged. One major area in nano-biotechnological research of agro-industrial byproducts is represented by the field of drug delivery systems (DDS). Among the main advantages of agro-industrial byproducts used as drug carriers are their abundance; low price; high biocompatibility; good biodegradability; moderate bioresorbability, associated with reduced systemic toxicity or even no toxicity; and often bioactivity. The goal of these efforts includes not only the possibility to characterize and manipulate matter on the nanoscale, but also to develop sustainable products and processes, including the development of platforms for drug delivery aiming for the treatment of pathologies such as cancer and diabetes. Indeed, there is great hope that the use of agro-industrial byproducts in nanobiotechnology will increase not only agricultural and livestock productivity, but will also contribute to other areas such as the development of DDS with new properties and low production costs; and sustainable environmental management due to the reuse of industrial discharged byproducts. This review will compile current findings on the use of byproducts as building blocks for modern drug carrier systems, emphasizing the challenges and promising applications.


Assuntos
Biotecnologia/métodos , Portadores de Fármacos/química , Resíduos Industriais/análise , Nanopartículas/química , Agricultura , Animais , Conservação dos Recursos Naturais/economia , Conservação dos Recursos Naturais/métodos , Portadores de Fármacos/economia , Sistemas de Liberação de Medicamentos/economia , Humanos , Resíduos Industriais/economia , Nanopartículas/economia , Nanotecnologia/métodos
10.
Rev. bras. oftalmol ; 72(5): 331-334, set.-out. 2013. graf, tab
Artigo em Português | LILACS | ID: lil-690705

RESUMO

OBJETIVO: Avaliar o custo do uso dos colírios lubrificantes mais utilizados no mercado nacional que apresentam na formulação o mesmo princípio ativo - carboximetilcelulose, considerando o número total de gotas presente em cada frasco dos colírios. MÉTODOS: Foi realizado um estudo experimental utilizando três frascos de cada um dos colírios Lacrifilm® (colírio 1) e Fresh Tears® (colírio 2). Para análise do custo dos colírios contou-se o número de gotas de cada frasco correlacionando os preços dos mesmos. O preço considerado para cada medicação foi o mínimo ao consumidor com alíquota de 17% publicado para o mês de janeiro de 2012. A análise estatística foi efetuada em SPSS® 18. A comparação das variáveis quantitativas analisadas foi procedida através do teste não paramétrico Mann-Whitney e correlação linear de Spearman, sendo considerada uma diferença estatisticamente significante um valor de probabilidade inferior a 0,05. RESULTADOS: Verificou-se que há diferença estatisticamente significativa entre as marcas de colírios avaliados com relação ao número total de gotas. O colírio 1 apresentou o maior número de gotas. CONCLUSÃO: O colírio 1, que tem o maior número de gotas por frasco, também é o que tem o preço mais acessível. Portanto, verifica-se que é o produto mais econômico, ou seja, o paciente pagará menos por cada gota.


OBJECTIVE: The objective of this study is to evaluate the cost of the use of lubricant eye drops, which are more used in the national market and contain in its formulation the same active ingredient - carboximeticelulose -, by considering their total number of drops in each flask. METHODS: An experimental study was accomplished by using three flasks of each one of the following eye drops: Lacrifilm®(eye drop 1) and Fresh Tears®(eye drop 2). To the analysis of their cost, the number of drops of each flask was counted, correlating them with their price. The price considered for each medication was the minimum to consumer with an aliquot of 17% published for the month of January 2012. The statistical analysis was accomplished in SPSS®18. The comparison of the quantitative variables evaluated was followed through the non-parametric test Mann-Whitney and Spearman linear correlation, in which a significant statistical difference was considered, a value of probability inferior to 0,05. RESULTS: It was verified statistically significant difference between brands of eye drops evaluated in relation to their total number of drops per flask as well as to their prices. Eye drop 1 presented greater number of drops. CONCLUSION: Eye drop 1, which has the greater number of drops per flask, also has the lowest price. Therefore, it is verified that the product is the most economical, what means that the patient will pay less for each drop.


Assuntos
Carboximetilcelulose Sódica/economia , Preço de Medicamento , Gastos em Saúde , Portadores de Fármacos/economia , Soluções Oftálmicas/economia , Brasil , Ensaio Clínico , Estudos de Avaliação como Assunto
11.
Drug Discov Today ; 18(19-20): 936-49, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23707660

RESUMO

In this review, we discuss the methodologies and platform technologies for enhancing the oral bioavailability of poorly soluble drugs. We also highlight the mechanisms of formulation technologies for improving desired physicochemical attributes of active substances. We focus on various commercial technologies, along with marketed products, and identify proprietary technologies protected by patents. We also discuss nonpropriety technologies, such as mesoporous silica, cyclodextrin complexation and solid dispersions. In addition, we highlight the factors affecting drug absorption and/or bioavailability, the methodologies available to prepare bioavailability-enhanced products, stability issues and examples of technology implementation.


Assuntos
Portadores de Fármacos/farmacocinética , Marketing/tendências , Tecnologia Farmacêutica/tendências , Administração Oral , Animais , Disponibilidade Biológica , Portadores de Fármacos/química , Portadores de Fármacos/economia , Humanos , Marketing/economia , Nanopartículas/química , Nanopartículas/economia , Nanopartículas/metabolismo , Solubilidade , Tecnologia Farmacêutica/economia
12.
Clin Cardiol ; 36(7): 407-13, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23595957

RESUMO

BACKGROUND: The economic impact of drug-eluting stent (DES) in-stent restenosis (ISR) is substantial, highlighting the need for cost-effective treatment strategies. HYPOTHESIS: Compared to plain old balloon angioplasty (POBA) or repeat DES implantation, drug-coated balloon (DCB) angioplasty is a cost-effective therapy for DES-ISR. METHODS: A Markov state-transition model was used to compare DCB angioplasty with POBA and repeat DES implantation. Model input parameters were obtained from the literature, and the cost analysis was conducted from a German healthcare payer's perspective. Extensive sensitivity analyses were performed. RESULTS: Initial procedure costs amounted to €3488 for DCB angioplasty and to €2782 for POBA. Over a 6-month time horizon, the DCB strategy was less costly (€4028 vs €4169) and more effective in terms of life-years (LYs) gained (0.497 versus 0.489) than POBA. The DES strategy incurred initial costs of €3167 and resulted in 0.494 LYs gained, at total costs of €4101 after a 6-month follow-up. Thus, DCB angioplasty was the least costly and most effective strategy. Base-case results were influenced mostly by initial procedure costs, target lesion revascularization rates, and the costs of dual antiplatelet therapy. CONCLUSIONS: DCB angioplasty is a cost-effective treatment option for coronary DES-ISR. The higher initial costs of the DCB strategy compared to POBA or repeat DES implantation are offset by later cost savings.


Assuntos
Angioplastia Coronária com Balão/economia , Angioplastia Coronária com Balão/instrumentação , Cateteres Cardíacos/economia , Fármacos Cardiovasculares/economia , Materiais Revestidos Biocompatíveis/economia , Reestenose Coronária/economia , Reestenose Coronária/terapia , Portadores de Fármacos/economia , Stents Farmacológicos/economia , Custos de Cuidados de Saúde , Paclitaxel/economia , Angioplastia Coronária com Balão/efeitos adversos , Fármacos Cardiovasculares/administração & dosagem , Reestenose Coronária/etiologia , Redução de Custos , Análise Custo-Benefício , Custos de Medicamentos , Alemanha , Humanos , Cadeias de Markov , Modelos Econômicos , Método de Monte Carlo , Paclitaxel/administração & dosagem , Inibidores da Agregação Plaquetária/economia , Inibidores da Agregação Plaquetária/uso terapêutico , Anos de Vida Ajustados por Qualidade de Vida , Fatores de Tempo , Resultado do Tratamento
13.
J Am Assoc Lab Anim Sci ; 51(2): 219-23, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22776122

RESUMO

The oral route is the most frequently used method of drug intake in humans. Oral administration of drugs to laboratory animals such as mice typically is achieved through gavage, in which a feeding needle is introduced into the esophagus and the drug is delivered directly into the stomach. This method requires technical skill, is stressful for animals, and introduces risk of injury, pain and morbidity. Here we investigated another method of drug administration. The benzimidazole derivative albendazole was emulsified in commercially available honey and administered to mice by voluntary feeding or gavage. Mice that received albendazole by either gavage or honey ingestion had virtually identical levels of serum albendazole sulfoxide, indicating that uptake and metabolism of albendazole was similar for both administration techniques. In addition, dosing mice with the albendazole-honey mixture for 8 wk had antiparasitic activity comparable to earlier studies using gavage for drug administration. Compared with gavage, voluntary ingestion of a drug in honey is more rapid, less stressful to the animal, and less technically demanding for the administrator. Because of its low cost and ready availability, honey presents a viable vehicle for drug delivery.


Assuntos
Albendazol/administração & dosagem , Anticestoides/administração & dosagem , Portadores de Fármacos , Emulsificantes/administração & dosagem , Mel , Administração Oral , Albendazol/sangue , Animais , Anticestoides/sangue , Carboximetilcelulose Sódica/administração & dosagem , Cromatografia Líquida de Alta Pressão/veterinária , Portadores de Fármacos/economia , Equinococose/tratamento farmacológico , Equinococose/veterinária , Emulsificantes/economia , Feminino , Mel/economia , Camundongos , Camundongos Endogâmicos BALB C , Doenças dos Roedores/tratamento farmacológico
14.
J Med Econ ; 15(4): 758-65, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22364285

RESUMO

OBJECTIVE: With the availability of several bowel cleansing agents, physicians and hospitals performing colonoscopies will often base their choice of cleansing agent purely on acquisition cost. Therefore, an easy to use budget impact model has been developed and established as a tool to compare total colon preparation costs between different established bowel cleansing agents. METHODS: The model was programmed in Excel and designed as a questionnaire evaluating information on treatment costs for a range of established bowel cleansing products. The sum of costs is based on National Health Service reference costs for bowel cleansing products. Estimations are made for savings achievable when using a 2-litre polyethylene glycol with ascorbate components solution (PEG+ASC) in place of other bowel cleansing solutions. Test data were entered into the model to confirm validity and sensitivity. The model was then applied to a set of audit cost data from a major hospital colonoscopy unit in the UK. RESULTS: Descriptive analysis of the test data showed that the main cost drivers in the colonoscopy process are the procedure costs and costs for bed days rather than drug acquisition costs, irrespective of the cleansing agent. Audit data from a colonoscopy unit in the UK confirmed the finding with a saving of £107,000 per year in favour of PEG+ASC when compared to sodium picosulphate with magnesium citrate solution (NaPic+MgCit). For every patient group the model calculated overall cost savings. This was irrespective of the higher drug expenditure associated with the use of PEG+ASC for bowel preparation. Savings were mainly realized through reduced costs for repeat colonoscopy procedures and associated costs, such as inpatient length of stay. CONCLUSIONS: The budget impact model demonstrated that the primary cost driver was the procedure cost for colonoscopy. Savings can be realized through the use of PEG+ASC despite higher drug acquisition costs relative to the comparator products. From a global hospital funding perspective, the acquisition costs of bowel preparations should not be used as the primary reason to select the preferred treatment agent, but should be part of the consideration, with an emphasis on the clinical outcome.


Assuntos
Orçamentos , Catárticos/economia , Ácido Cítrico/economia , Colonoscopia/economia , Compostos Organometálicos/economia , Fosfatos/economia , Picolinas/economia , Polietilenoglicóis/economia , Catárticos/administração & dosagem , Citratos , Ácido Cítrico/administração & dosagem , Custos e Análise de Custo/métodos , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/economia , Humanos , Modelos Econômicos , Compostos Organometálicos/administração & dosagem , Fosfatos/administração & dosagem , Picolinas/administração & dosagem , Polietilenoglicóis/administração & dosagem , Medicina Estatal , Inquéritos e Questionários , Reino Unido
15.
EMBO Mol Med ; 4(1): 3-14, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22162462

RESUMO

Cardiovascular diseases are the most common causes of human morbidity and mortality despite significant therapeutic improvements by surgical, interventional and pharmacological approaches in the last decade. MicroRNAs (miRNAs) are important and powerful mediators in a wide range of diseases and thus emerged as interesting new drug targets. An array of animal and even human miRNA-based therapeutic studies has been performed, which validate miRNAs as being successfully targetable to treat a wide range of diseases. Here, the current knowledge about miRNAs therapeutics in cardiovascular diseases on their way to clinical use are reviewed and discussed.


Assuntos
Doenças Cardiovasculares/terapia , MicroRNAs/uso terapêutico , Animais , Arritmias Cardíacas/terapia , Aterosclerose/terapia , Portadores de Fármacos/química , Portadores de Fármacos/economia , Portadores de Fármacos/farmacocinética , Humanos , Neovascularização Fisiológica , Oligonucleotídeos/química , Oligonucleotídeos/uso terapêutico
18.
Acc Chem Res ; 41(1): 40-9, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18159936

RESUMO

This Account provides an overview and examples of function-oriented synthesis (FOS) and its increasingly important role in producing therapeutic leads that can be made in a step-economical fashion. Biologically active natural product leads often suffer from several deficiencies. Many are scarce or difficult to obtain from natural sources. Often, they are highly complex molecules and thus not amenable to a practical synthesis that would impact supply. Most are not optimally suitable for human therapeutic use. The central principle of FOS is that the function of a biologically active lead structure can be recapitulated, tuned, or greatly enhanced with simpler scaffolds designed for ease of synthesis and also synthetic innovation. This approach can provide practical access to new (designed) structures with novel activities while at the same time allowing for synthetic innovation by target design. This FOS approach has been applied to a number of therapeutically important natural product leads. For example, bryostatin is a unique natural product anticancer lead that restores apoptosis in cancer cells, reverses multidrug resistance, and bolsters the immune system. Remarkably, it also improves cognition and memory in animals. We have designed and synthesized simplified analogs of bryostatin that can be made in a practical fashion (pilot scale) and are superior to bryostatin in numerous assays including growth inhibition in a variety of human cancer cell lines and in animal models. Laulimalide is another exciting anticancer lead that stabilizes microtubules, like paclitaxel, but unlike paclitaxel, it is effective against multidrug-resistant cell lines. Laulimalide suffers from availability and stability problems, issues that have been addressed using FOS through the design and synthesis of stable and efficacious laulimalide analogs. Another FOS program has been directed at the design and synthesis of drug delivery systems for enabling or enhancing the uptake of drugs or drug candidates into cells and tissue. We have generated improved transporters that can deliver agents in a superior fashion compared with naturally occurring cell-penetrating peptides and that can be synthesized in a practical and step-economical fashion. The use of FOS has allowed for the translation of exciting, biologically active natural product leads into simplified analogs with superior function. This approach enables the development of synthetically innovative strategies while targeting therapeutically novel structures.


Assuntos
Antineoplásicos/síntese química , Antineoplásicos/economia , Fatores Biológicos/química , Desenho de Fármacos , Neoplasias/tratamento farmacológico , Antineoplásicos/química , Fatores Biológicos/farmacologia , Portadores de Fármacos/síntese química , Portadores de Fármacos/economia , Portadores de Fármacos/farmacologia , Conformação Molecular , Estereoisomerismo
19.
Expert Opin Drug Deliv ; 3(6): 799-807, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17076601

RESUMO

Foams offer an innovative and more convenient means of topical drug delivery. The successful introduction of hydroalcoholic foams paved the way for the development of a new generation of foam products that provide skin barrier build-up and hydration. Such foams, designated as emollient foams consist of oil-in-water or water-in-oil emulsions with necessary excipients, such as non-ionic surfactants, gelling agents and foam adjuvants. Emollient foams can carry a broad variety of topical drugs, including water-soluble, oil-soluble and suspended active agents. This paper reviews emollient foam compositions and their physicochemical properties. It further accounts for the usability and functional advantages of emollient foam as a vehicle of topical drugs, including: i) improved usability, which affects treatment, compliance and, consequently, improves therapeutic results; ii) safety; iii) controllable drug delivery; iv) skin barrier build-up and hydration; and v) enhanced clinical efficacy.


Assuntos
Portadores de Fármacos/administração & dosagem , Emolientes/administração & dosagem , Administração Tópica , Animais , Portadores de Fármacos/economia , Emolientes/economia , Emulsões , Humanos , Marketing
20.
Expert Opin Drug Deliv ; 2(3): 587-95, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-16296777

RESUMO

Over the last 100 years tablets have grown from first invention to becoming the world's leading medicinal form, by any measure. This article considers some of the reasons for the pre-eminence of pharmaceutical tablets. Particular attention has been given to the role of controlled-release tablets and to a very versatile hydrogel-based controlled-release technology, called TIMERx((R)). The unique nature of TIMERx intermolecular physical chemistry is described in relation to the technology's potential to provide any one of a number of different release profiles, ranging from zero order to chronotherapeutic release. The unusual nature of TIMERx technology lies in its ability to provide different release kinetics by the manipulation of molecular interactions. This 'molecular engine' replaces the need for complex processing or novel excipients and allows desired drug release profiles to be 'factory set' following a simple formulation development process. The article describes the physico-chemical interactions of TIMERx technology at a molecular level and how they can be manipulated by formulation considerations. The article describes how TIMERx technology has been developed to the point where today it underpins a number of marketed pharmaceutical CR products as well as products under development by Penwest Pharmaceuticals.


Assuntos
Preparações de Ação Retardada , Portadores de Fármacos/farmacocinética , Trato Gastrointestinal/metabolismo , Polissacarídeos/farmacocinética , Tecnologia Farmacêutica , Ensaios Clínicos como Assunto , Preparações de Ação Retardada/economia , Portadores de Fármacos/química , Portadores de Fármacos/economia , Humanos , Polissacarídeos/química , Polissacarídeos/economia , Tecnologia Farmacêutica/economia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...